Developing storyline

Novo Nordisk's mixed drug trial results across therapies

Novo Nordisk reports contrasting 2026 trial outcomes, halting ziltivekimab heart-failure studies over futility while its semaglutide-based Wegovy program posts strong pediatric obesity results.

3 stories19 sourcesUpdated Sep 8, 2026

In this storyline:myocardial infarction obesity ziltivekimab Wegovy heart failure semaglutide glucagon-like peptide-1 Novo Nordisk

Key developments

Sep 7, 2026
Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active.
8 sources on this →
Sep 7, 2026
Novo Nordisk's STEP Young trial shows once-weekly semaglutide plus lifestyle changes lifted 40.4% of children aged 6-11 with obesity out of the obesity category after 68 weeks.
6 sources on this →
Sep 8, 2026
GLP-1 prescriptions for children have surged more than 30,000% since 2019, underscoring rapid growth in pediatric use of drugs like Novo Nordisk's Wegovy.
5 sources on this →

Coverage across the spectrum

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Stories in this storyline

Health

Novo Nordisk Halts Two Ziltivekimab Heart Trials

Novo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.

8 sources

Health

GLP-1 prescriptions for kids up more than 30,000% since 2019

5 sources

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Novo says Wegovy trial moved 40% of young children out of obesity

In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.

6 sources